Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
Total Valuation
Edgewise Therapeutics has a market cap or net worth of $1.22B. The enterprise value is $2.02B.
Market Cap$1.22B
Enterprise Value$2.02B
Share Statistics
Edgewise Therapeutics has 105.14M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding105.14M
Owened by Insiders31.71%
Owened by Instutions<0.01%
Financial Efficiency
Edgewise Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -34.23%.
Return on Equity (ROE)-29.14%
Return on Assets (ROA)-27.49%
Return on Invested Capital (ROIC)-34.23%
Return on Capital Employed (ROCE)-34.31%
Revenue Per Employee$0
Profits Per Employee-$1,216,481.818
Employee Count110
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Edgewise Therapeutics is -18.44. Edgewise Therapeutics’s PEG ratio is 2.41.
PE Ratio-18.44
PS Ratio0.00
PB Ratio5.37
Price to Fair Value5.37
Price to FCF-22.36
Price to Operating Cash Flow-22.63
PEG Ratio2.41
Income Statement
In the last 12 months, Edgewise Therapeutics had revenue of $0.00 and earned -$133.81M in profits. Earnings per share was -$1.45.
Revenue$0.00
Gross Profit$0.00
Operating Income-$158.83M
Pretax Income-$133.81M
Net Income-$133.81M
EBITDA-158.83M
Earnings Per Share (EPS)-1.45
Cash Flow
In the last 12 months, operating cash flow was -$109.03M and capital expenditures -$1.31M, giving a free cash flow of -$110.34M billion.
Operating Cash Flow-$109.03M
Free Cash Flow-$110.34M
Free Cash Flow per Share-$1.05
Dividends & Yields
Edgewise Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-4.47%
Earnings Yield-5.42%
Stock Price Statistics
Beta2.42
52-Week Price Change-30.70%
50-Day Moving Average23.63
200-Day Moving Average25.29
Relative Strength Index (RSI)28.86
Average Volume (3m)2.54M
Important Dates
Edgewise Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Edgewise Therapeutics as a current ratio of 19.93, with Debt / Equity ratio of 0.01
Current Ratio19.93
Quick Ratio19.93
Debt to Market Cap<0.01
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Edgewise Therapeutics has paid $0.00 in taxes.
Income Tax$0.00
Effective Tax Rate0.00%
Enterprise Valuation
Edgewise Therapeutics EV to EBITDA ratio is -15.30, with an EV/FCF ratio of -22.03.
EV to Sales0.00
EV to EBITDA-15.30
EV to Free Cash Flow-22.03
EV to Operating Cash Flow-22.29
Balance Sheet
Edgewise Therapeutics has $470.17M in cash and marketable securities with $4.74M in debt, giving a net cash position of -$465.43M billion.
Cash & Marketable Securities$470.17M
Total Debt$4.74M
Net Cash-$465.43M
Net Cash Per Share-$4.43
Tangible Book Value Per Share$4.97
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Edgewise Therapeutics is $42.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.75
Price Target Upside274.34%
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast
EPS Growth Forecast7.97%